Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.95 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.95 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.95 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.95 |
| ▸ | CES2 | O00748 | 1/20 | 0.67 |
| ▸ | CES1 | P23141 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | PKM | P14618 | 2/20 | 0.58 |
| ▸ | GSK3B | P49841 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2-Picolinic Acid SCHEMBL28737810 | 0.98 | LMNA (1.00) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| 2-Picolinic Acid SCHEMBL29368665 | 0.98 | — | — | |
| 2-Picolinic Acid SCHEMBL674837 | 0.98 | LMNA (1.00) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| 2-Picolinic Acid SCHEMBL7457912 | 0.98 | LMNA (1.00) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| 2-Picolinic Acid SCHEMBL36055 | 0.98 | — | — | |
| 2-Picolinic Acid SCHEMBL15401824 | 0.95 | LMNA (0.95) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| 2-Picolinic Acid SCHEMBL5203401 | 0.95 | LMNA (0.95) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| 2-Picolinic Acid SCHEMBL2168036 | 0.95 | LMNA (0.95) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| 2-Picolinic Acid SCHEMBL20721125 | 0.95 | LMNA (0.95) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| 2-Picolinic Acid SCHEMBL22835776 | 0.95 | LMNA (0.95) | LMNAL3MBTL1NAPRTP4HTMCES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1411965-A4 | METHODS AND COMPOSITIONS FOR CONTROLLING PROTEIN ASSEMBLY OR AGGREGATION | NOVACTYL INC (US) | 2006-01-11 | — | — | EP | claimed |
| EP-1411965-A1 | METHODS AND COMPOSITIONS FOR CONTROLLING PROTEIN ASSEMBLY OR AGGREGATION | Novactyl, Inc. (US) | 2004-04-28 | — | — | EP | claimed |
| WO-2003006044-A1 | METHODS AND COMPOSITIONS FOR CONTROLLING PROTEIN ASSEMBLY OR AGGREGATION | NOVACTYL, INC. (US) | 2003-01-23 | — | — | WO | claimed |
| US-20020037908-A1 | Methods and compositions for controlling protein assembly or aggregation | NOVACTYL, INC. | 2002-03-28 | — | — | US | claimed |
| US-20250255920-A1 | Controlled-Release and Stratified Cyclodextrin Inclusion Complex Vehicles | CZAP RES AND DEVELOPMENT LLC (US) | 2025-08-14 | — | — | US | disclosed |
| US-20250177457-A1 | SUPPLEMENT COMPOSITION FOR CONSUMPTION BY INDIVIDUALS BEING ADMINISTERED A GLP-1 AGONIST | Food Sciences Corp. | 2025-06-05 | — | — | US | disclosed |
| US-12285455-B2 | Controlled-release and stratified cyclodextrin inclusion complex vehicles | CZAP RESERACH AND DEVELOPMENT, LLC (US) | 2025-04-29 | — | — | US | disclosed |
| US-20230405074-A1 | CONTROLLED-RELEASE AND STRATIFIED CYCLODEXTRIN INCLUSION COMPLEX VEHICLES | CZAP RESEARCH AND DEVELOPMENT, LLC | 2023-12-21 | — | — | US | disclosed |
| US-11766472-B2 | Method of treatment for hair loss | RAJPUT RAJENDRASINGH JALAMSINGH (IN) | 2023-09-26 | — | — | US | disclosed |
| EP-3892303-B1 | CONTROLLED-RELEASE AND STRATIFIED CYCLODEXTRIN INCLUSION COMPLEX VEHICLES | CZAP RES AND DEVELOPMENT LLC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-11633448-B2 | Controlled-release and stratified cyclodextrin inclusion complex vehicles | CZAP RESEARCH AND DEVELOPMENT LLC (US) | 2023-04-25 | — | — | US | disclosed |
| EP-4098282-A1 | CONTROLLED-RELEASE AND STRATIFIED CYCLODEXTRIN INCLUSION COMPLEX VEHICLES | Czap Research And Development, LLC (US) | 2022-12-07 | — | — | EP | disclosed |
| US-20020037967-A1 | Process for producing blends of syndiotactic 1,2-polybutadiene and rubbery elastomers with a chromium-based catalyst system | BRIDGESTONE CORPORATION (JP) | 2002-03-28 | — | — | US | disclosed |
| EP-1183283-A1 | MOLYBDENUM-BASED CATALYST COMPOSITION FOR POLYMERIZING CONJUGATED DIENES | BRIDGESTONE CORPORATION (JP) | 2002-03-06 | — | — | EP | disclosed |
| US-6348550-B1 | ADDITION POLYMERIZATION OF 1,3-BUTADIENE TO SYNDIOTACTIC 1,2-POLYBUTADIENE USING COORDINATION CATALYST COMPRISING MOLYBDENUM COMPOUND, A HYDROGEN PHOSPHITE, AND MIXTURE OF (NON)STERICALLY HINDERED ORGANOALUMINUM COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2002-02-19 | — | — | US | disclosed |
| US-6303692-B1 | PROVIDING MIXTURE OF RUBBER CEMENT AND 1,3-BUTADIENE; POLYMERIZING INTO SYNDIOTACTIC 1,2-POLYBUTADIENE BY USING CATALYST FORMULATION COMPRISING MOLYBDENUM COMPOUND, HYDROGEN PHOSPHITE COMPOUND AND ORGANOALUMINUM COMPOUND | BRIDGESTONE CORPORATION (JP) | 2001-10-16 | — | — | US | disclosed |
| WO-2000075201-A1 | MOLYBDENUM-BASED CATALYST COMPOSITION FOR POLYMERIZING CONJUGATED DIENES | BRIDGESTONE CORPORATION (JP) | 2000-12-14 | — | — | WO | disclosed |
| EP-0514451-B1 | DIETARY SUPPLEMENTS COMPRISING VITAMINS AND MINERALS | LIFESCIENCE CORP (US) | 1997-01-15 | — | — | EP | disclosed |
| EP-0514451-A1 | DIETARY SUPPLEMENTS COMPRISING VITAMINS AND MINERALS. | UNIV TEXAS (US) | 1992-11-25 | — | — | EP | disclosed |
| WO-1991011117-A2 | DIETARY SUPPLEMENTS COMPRISING VITAMINS AND MINERALS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1991-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037908-A1 | Methods and compositions for controlling protein assembly or aggregation | PSEN1, PSEN2, PRNP | LMNA 1073/4885L3MBTL1 4530/4885NAPRT 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.